Related Experiment Video

Updated: Jul 4, 2026

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

Mild cognitive impairment: searching for the prodrome of Alzheimer's disease

Paul B Rosenberg1, Constantine Lyketsos

  • 1Division of Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University School of Medicine, 5300 Alpha Commons Drive, Baltimore, MD 21205, USA.

World Psychiatry : Official Journal of the World Psychiatric Association (WPA)
|June 20, 2008
PubMed

Insights

Mild cognitive impairment (MCI) signals a high risk for dementia, especially Alzheimer's disease (AD). While medications show limited success, lifestyle changes may help prevent MCI progression.

Area of Science:

  • Neurology
  • Geriatrics
  • Cognitive Science

Background:

  • Mild cognitive impairment (MCI) represents a transitional stage between normal cognition and dementia.
  • MCI is increasingly recognized as a significant risk factor for developing dementia, particularly Alzheimer's disease (AD).
  • MCI is more prevalent than dementia and is closely linked to the aging process.

Purpose of the Study:

  • To highlight MCI as a key target population for Alzheimer's disease (AD) prevention strategies.
  • To review clinical and biological markers associated with MCI prognosis.
  • To discuss current and potential interventions for preventing the progression of MCI to dementia.

Main Methods:

  • Review of existing clinical and biological markers predictive of MCI prognosis.
  • Analysis of clinical trial outcomes for medications aimed at preventing MCI progression.
  • Examination of observational data on lifestyle modifications for MCI prevention.

Main Results:

  • Depressive symptoms, cognitive deficits, and specific neuroimaging/neurochemical findings are predictive of MCI prognosis.
  • Current medication trials for preventing MCI progression to dementia have yielded largely negative results.
  • Observational data suggest lifestyle interventions like exercise, cognitive stimulation, and social engagement may be beneficial.

Conclusions:

  • MCI is a critical stage for early intervention in Alzheimer's disease (AD) prevention.
  • Mood symptoms in MCI are common and potentially treatable, requiring clinical attention.
  • Lifestyle modifications show promise for preventing MCI progression, alongside novel therapies in development for early AD.
Keywords:
Alzheimer's diseaseMild cognitive impairmentagingdepressive symptomsexerciseprevention

More Related Videos

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease06:23

The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease

Published on: October 13, 2016

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment08:43

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Published on: August 7, 2017

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...